EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Genetic Predisposition to Sarcoma: What Should Clinicians Know?

Jennie Vagher, Casey J Mehrhoff, Vaia Florou, Luke D Maese

Current Treatment Options in Oncology · 2024

DOI: 10.1007/s11864-024-01192-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Jennie Vagher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA. Hauptthemen laut MEDLINE: Sarcoma, Genetic Predisposition to Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Pathogenic germline variants in the setting of several associated cancer predisposition syndromes (CPS) may lead to the development of sarcoma. We would consider testing for a CPS in patients with a strong family history of cancer, multiple primary malignancies, and/or pediatric/adolescent/young adult patients diagnosed with other malignancies strongly associated with CPS. When a CPS is diagnosed in a patient with sarcoma, additional treatment considerations and imaging options for those patients are required. This applies particularly to the use of radiation therapy, ionizing radiation with diagnostic imaging, and the use of alkylating chemotherapy. As data and guidelines are currently lacking for many of these scenarios, we have adopted a shared decision-making process with patients and their families. If the best chance for cure in a patient with CPS requires utilization of radiation therapy or alkylating chemotherapy, we discuss the risks with the patient but do not omit these modalities. However, if there are treatment options that yield equivalent survival rates, yet avoid these modalities, we elect for those options. Considering staging imaging and post-therapy evaluation for sarcoma recurrence, we avoid surveillance techniques that utilize ionizing radiation when possible but do not completely omit them when their use is indicated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaGenetic Predisposition to DiseaseHumansGerm-Line MutationGenetic TestingDisease ManagementClinical Decision-MakingCombined Modality Therapy

Stichwörter der Autor:innen

AlkylatorCancer predisposition syndromePediatric cancerRadiationSarcoma

Autor:innen und Institutionen

  • Department of Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Division of Hematology/Oncology, Primary Children's Hospital, University of Utah, 100 Mario Capecchi Dr, Salt Lake City, UT, 84113, USA.
  • Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
  • Department of Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA. Luke.Maese@hsc.utah.edu.
  • Division of Hematology/Oncology, Primary Children's Hospital, University of Utah, 100 Mario Capecchi Dr, Salt Lake City, UT, 84113, USA. Luke.Maese@hsc.utah.edu.

Zitieren

APA

Vagher, J., Mehrhoff, C. J., Florou, V., & Maese, L. D. (2024). Genetic Predisposition to Sarcoma: What Should Clinicians Know?. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01192-6

Vancouver

Vagher J, Mehrhoff CJ, Florou V, Maese LD. Genetic Predisposition to Sarcoma: What Should Clinicians Know?. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01192-6

BibTeX
@article{Vagher2024,
  author = {Vagher, Jennie and Mehrhoff, Casey J and Florou, Vaia and Maese, Luke D},
  title = {Genetic Predisposition to Sarcoma: What Should Clinicians Know?},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  doi = {10.1007/s11864-024-01192-6}
}
Kostenlos starten →